Therapy for Nontuberculous Mycobacterial Lung Disease Shows Promise

Data found that a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy had benefits for nontuberculous mycobacterial (NTM) lung disease patients.